APA (7th ed.) Citation

A, S., F, H., J, L., P, S., C, S., M, D., . . . TF, B. (2022). Safety and Antiviral Activity of EGFR Inhibition by Erlotinib in Chronic Hepatitis C Patients: A Phase Ib Randomized Controlled Trial. Clinical and translational gastroenterology, 13(6), e00492. https://doi.org/10.14309/ctg.0000000000000492

Chicago Style (17th ed.) Citation

A, Saviano, Habersetzer F, Lupberger J, Simo-Noumbissie P, Schuster C, Doffoël M, Schmidt-Mutter C, and Baumert TF. "Safety and Antiviral Activity of EGFR Inhibition by Erlotinib in Chronic Hepatitis C Patients: A Phase Ib Randomized Controlled Trial." Clinical and Translational Gastroenterology 13, no. 6 (2022): e00492. https://doi.org/10.14309/ctg.0000000000000492.

MLA (9th ed.) Citation

A, Saviano, et al. "Safety and Antiviral Activity of EGFR Inhibition by Erlotinib in Chronic Hepatitis C Patients: A Phase Ib Randomized Controlled Trial." Clinical and Translational Gastroenterology, vol. 13, no. 6, 2022, p. e00492, https://doi.org/10.14309/ctg.0000000000000492.